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Abstract Impaired renal function is an important cause for the oedema formation, which often occurs in severe
chronic obstructive pulmonarydisease (COPD).
Inthe present study, the importance of nocturnalhypoxaemia (measuredbya nocturnalpulse oximetry) for therenal
functionwas determined in19 COPD patients, with normal levels of serum creatinine.The effects on kidney function of
alleviating the nocturnal hypoxaemia [using 6 months of long-term oxygen treatment (LTOT)], was assessed in 12 pa-
tients. Renal function was assessed by determining the clearances of intravenously administered inulin (CIn) and para-
amino-hippurate (CPAH) and orally supplemented lithium (CLi) and of circulating sodium (CNa).The19 patients had amean
PaO2 of 7.6371.08 kPa, a PaCO2 of 5.9870.85kPa, ameannocturnaloxygen saturation (MnSaO2) of 87.772.8% and an
FEV1in %Pof 25.6714.6%.CIn and CPAH were 35 and 45% lower thannormal, respectively, whereas CIn/CPAH=filtration
fraction (FF) was 31% higher than normal. Six months of LTOT in 12 of the patients was not followed by any significant
change in renal function in the entire study group.However, low pretreatment MnSaO2 correlated with reductions in
post-treatment (FF) (r=0.73, Po0.05). Post-treatment PaCO2 did not change significantly in patients treated with oral
diuretics, but increased (Po0.05) in patientswithoutdiuretics.CNa decreased after LTOT in six patientswith an increase
in PaCO2 46%, but CNa increased in four patients with unchanged or decreased PaCO2 following LTOT.Conclusions:
Renal function (including filtration fraction) is impaired inhypoxaemic COPD.Filtration fraction is decreased following 6
months of LTOTsolely in patientswith severe pretreatment hypoxaemia and sodium clearance seems to be increased if
improved oxygenation is not accompanied byincreased PaCO2.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1401, available online at http://www.sciencedirect.com
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fraction; nocturnal hypoxaemia; long-term oxygen treatment; chronic obstructive pulmonary disease; hypercapnia.INTRODUCTION
Water and salt retention eventually resulting in oedema
formation is a frequently occurring feature in severe
chronic obstructive pulmonary disease (COPD) (1). Oe-
dema formation is more common during exacerbations
ofCOPD (2).Exacerbations are associatedwith impaired
arterial blood gases, increased pulmonary pressures and
increased afterload of the right ventricle of the heart (2).
However, at least in stable severeCOPD, oedema forma-Received 8 April 2002, accepted in revised form 24 June 2002
Correspondence shouldbe addressed to:DrTomas Bratel,MD,Division
of RespiratoryMedicine,DepartmentofMedicine,KarolinskaHospital,
S-17176 Stockholm, Sweden.Fax: +46 8 33 29 98; E-mail:
tomas.bratel@ks.setion may be noticed irrespective of the concurrence of
pulmonary hypertension and decreased right ventricular
cardiac function (3). Impaired renal function, particularly
renal vasoconstriction leading to diminished renal plas-
ma £ow (RPF), has therefore been implicated as an addi-
tive factor for the oedema formation in COPD (4,5).
Hypercapnia has in some studies been noticed as the
onlydecisive factor leading to renal dysfunction in COPD
(1,6,7).On the other hand, in other studies hypoxaemia,
air £ow obstruction or hormonal alterations such as in-
creased catecholamine or endothelin production have
been considered to be at least partially accountable for
the renal vasoconstriction and reduced RPF in COPD
(8,9).However, other renal functions, as for exampleglo-
merular ¢ltration rate (GFR) or the salt load delivered
to the distal tubules (10) may be a¡ected by blood gas
RENALFUNCTIONINHYPOXAEMICCOPD 309aberrations and itmay therefore be of importance to as-
sess such functions.
Nocturnal hypoxaemia in COPD is associatedwith in-
creasednocturnal catecholamine excretion (11) aswell as
daytime pulmonary hypertension (12).Nocturnal hypox-
aemia in other diseases as for example obstructive sleep
apnoea is associated with various hormonal alterations
as well as altered renal excretion of salt and water
(13,14). To our knowledge, there has been no report on
the possible relationship between nocturnal hypoxaemia
in COPD and daytime renal function.
The e¡ects of improvedoxygenation onrenal function
in COPD has only been investigated in short-term stu-
dies (4,5,10), despite that prospective studies of oxygen
therapy imply that the bene¢cial e¡ects on, for example,
pulmonary circulation aremore obvious after long-term
oxygen therapy (LTOT) than after acute oxygen supple-
mentation (15).
The aim of the present study was to investigate
renal function in severe COPD patients with varying
degrees of air £ow obstruction and daytime blood gas
impairments. The renal function was related to forced
expiratory volumes, daytime blood gases and to the
level of nocturnal hypoxaemia. A subgroup of the pa-
tients was subjected to at least 4 months of LTOT and
a further aim was to study the possible long-term
e¡ects on renal function associated with the post-
treatment improvement of daytime and nocturnal
oxygenation.TABLE 1. Antropomorphic, lung function, gas exchange data in
after 6 months of LTOT
Before LTOT
(n=19)
BMI (kg/m2) 22.774.4
Hb (g/l) 146.6713.1
Pulse (beats/min) 84.5712.0
MAP (mmHg) 92.0713.0
FEV1 (%P) 25.6714.6
FVC (%P) 52.5723.3
FEV1/FVC (%) 39.079.4
PaO2 (kPa) 7.6371.08
PaCO2 (kPa) 5.9870.85
pH 7.4170.04
MnSaO2 (%) 87.772.8
Nadir SaO2 (%) 76.377.7
%t SaO2o90% 63.1727.9
%t SaO2o85% 11.6718.6
Abbreviations:BMI=bodymass index;Hb=haemoglobin;MA
1s;FVC=forcedvital capcity;PaO2 and PaCO2= arterial tension
saturation during a nocturnal recording; %t SaO2o90 and
in percentage of the nocturnal recording. Note that blood ga
ongoing oxygen supplemenatation. Signi¢cantly di¡erent pos
***=Po0.05,o0.01,o0.001.SUBJECTS
Nineteen patients (10 males) who all su¡ered frommod-
erate to severe airway obstruction (forced expiratory
volume in 1s (FEV1) in percentage of predicted (%P)
o70% and FEV1/forced vital capacity (FVC)o65%) were
included in the study. All patients were investigatedwith
regard to their possible need for LTOT. Four patients
were considered not hypoxaemic enough to receive
LTOT (PaO248.5kPa). The patients (n=15) who were
deemed eligible for LTOT had quit smoking at least 4
weeks prior to the start of the study.These 15 patients
had an arterial oxygen tension (PaO2) o7.3kPa while
breathing ambient air (n=5) or a PaO2 of 7.3^7.9 kPa
(n=7) or PaO2 of 8.0^8.3kPa (n=3) but with substantial
nocturnal hypoxaemia (arterial oxygen saturation
(SaO2)o90%, lasting425% of the nocturnal recording)
in association with previous episodes of oedema. How-
ever, onehypoxaemic patientmoved to another area, an-
other one declined oxygen treatment and in yet another
one, LTOT was discontinued due to subsequently im-
proved oxygenation on air breathing. Thus, the 12 re-
maining hypoxaemic patients were investigated both
before and after at least 4 months of LTOT (Table1).
Five of the 19 patients had PaCO2 levels above 6.5kPa
(range 6.7^7.9kPa) and the rest had PaCO2 values
o6.5kPa while breathing ambient air. All 19 patients ex-
cept one had serum creatinine levels below the upper re-
ference limit of our laboratory (120mmol/l) and all patients19 COPD patients before LTOTand in12 patients before and
Before LTOT
(n=12)
After LTOT
(n=12)
23.074.1 22.474
151.4710.6 146.378.2
85.3710.5 82.5711.1
93.8715.9 89.8712.6
28.5717.9 28.2716.5
60.3727.3 60.7724.6
37.5711.3 37.7714.6
7.2971.07 9.1470.74***
5.8970.89 6.2570.81
7.4270.04 7.4070.02
87.172.9 93.672.2***
76.678.5 82.774.8*
70.6725.5 8.3714.7***
12.0719.6 0.671.2**
P=mean arterial pressure; FEV1=forced expiratory volume in
ofoxygen andcarbondioxide;MnSaO2: mean arterialoxygen
o85%=cumulative time spent with SaO2o90 and o85%
ses and oxygen saturation after LTOTwere all taken during
t-treatment levels compared to values before LTOT: *, **,
310 RESPIRATORYMEDICINEwere in a stable cardiopulmonary state (as judgedby com-
parisons with previous pulmonary X-rays, dynamic spiro-
metries and electrocardiograms) at the time of the study.
One patient had moderately elevated mean arterial pul-
monarypressure (40mmHg) because ofmoderate COPD
combinedwith aprevious episode of lungembolism.Twelve
of the19 patients used furosemide 40^120mg/day because
of previous episodes of oedema and 11 medicated with
slow-release theophyllinepreparations.Eight of the12 sub-
jects who were investigated after at least 4 months of
LTOTmedicatedwith oral theophylline.
Thepatient’s levels of inulin (In) andpara-amino-hippu-
ric acid (PAH) clearancewere comparedwith those of 24
healthy normotensivemales (all aged 63 years) who have
been described previously (16). Although, our patients
were signi¢cantly older (68.770.6 years) than these
healthy subjects the di¡erence amounted to only 6
years.The other renal parameters were compared with
themean levels of corresponding parameters in two po-
pulations of younghealthy subjectswith amean age of 32
and 34 years respectively (17,18).
The study was approved by the ethical committee of
Huddinge University hospital and all patients gave their
informed consent to participate in the study.
METHODS
Following a physical examination, venous samples were
drawn for assessment of haemoglobin, creatinine and
electrolytes using routine laboratory methods. Forced
expiratory volumesweremeasuredbydynamic spirome-
try (Vitalographs, Buckingham, England) in the after-
noon about 30min after b2- stimulation. The best of
three assessments of FEV1was used for statistical analy-
sis and FVC as well as the ratio between the two (FEV1/
FVC) was taken from thatmeasurement.
A nocturnal ¢nger pulse oximetry (Radiometer A/S,
Copenhagen, Denmark) was executed the following
night without oxygen supplement.Mean arterial oxygen
saturation for the whole night (MnSaO2) was calculated
and the cumulative time with an SaO2 level o90 and
o85%, respectively, in percentage of the total nocturnal
recording time was estimated. Systemic blood pressure
was measured while the patient was resting in bed at ca
06.00 a.m. Arterial bloodgases (ABL 520,Radiometer A/
S) were drawn with the patient resting in a semirecum-
bent position at 06.00^07.00 in the morning following
the nocturnal pulse oximetry.
All oximetry tracings were scrutinised manually by
the same observer (MR) without knowledge of the out-
come of the renal functional studies.
Twelve hours before the renal clearance tests, the pa-
tients received16.2mmol of lithium carbonate (Li) orally.
After an overnight fast (the samenight the oximetry was
performed) each patientdrank 500ml of water and thenthe urinary bladder was emptied.Thereafter starting at
08.00h a.m. the patient drank 7.5ml/kg body weight of
water/h during 3h.During this time the patient received
infusions of 25% inulin (Inutests, Kemi£our, Stockholm,
Sweden; after a priming dose of 0.2ml/kg body weight, a
constant infusion of 0.5ml/min was given) and 20% para-
amino hippuric acid (Merck Sharp and Dohme, West
Point, U.S.A.; after a priming dose of 0.03ml/kg body
weight, a constant infusion of 0.5ml/min was given).The
levels of In, PAH, lithium and sodium were assessed in
plasma and in urine, and themean of plasma levels taken
at the beginning and the end of a 45min period aswell as
the urinary level of the 45min periodwas used for clear-
ance calculations (18). Finally, the mean value of four
45min sampling periods (i.e. 3 h) was used for statistical
analysis.The clearance (C) of a substance was calculated
by the formula: C=urinary levelvolume/plasma level
and corrected for 1.73m2 of body area. The ¢ltration
fraction (FF) was estimated by CIn/CPAH. The salt and
water load to the proximal and indirectly to the distal
renal tubule and thus, the sodium reabsorption within
the proximal and distal tubules can be accurately as-
sessed by measuring the clearance of orally supplemen-
ted lithium (CLi) (19).
The fractional and absolute levels of proximal sodium
reabsorptionwere calculatedby1(CLi/CIn)100% and PNa
(CIn CLi) (mmol/min), respectively. The fractional and
absolute levels of distal sodium (Na) reabsorption were
calculated by1^(CNa/CLi)100% and PNa (CLi CNa) (mmol/
min) (17,18).
All of these measurements were repeated in 12 pa-
tients following 6.270.9 months of LTOT.The oralmedi-
cationwas kept unaltered and the patient’s ordinary diet
was continued throughout the study period. At the sec-
ond measurement, the nocturnal oximetry and the
morning (at 06.00 a.m.) blood gases were performed
during ongoing oxygen supplementation.Oxygen supple-
mentationwas discontinued at 07.45 a.m.The renal clear-
ance tests were performed during ambient air breathing
between ca 08.30 and11.30 a.m. bothbefore and after six
months of LTOT.
STATISTICALANALYSIS
Parametric and non-parametric tests were used accord-
ing to distribution.Results were presented asmean7SD.
Correlations between variables were assessed by linear
regression (r) or by spearman rank correlation (rs).
Changes over timewere determined by Student’s paired
t-test or Wilcoxon’s signed-rank test.The change follow-
ing treatment in the individual level of a parameter was
estimatedby the ratio between the value after 6months
of LTOTand the pretreatment value and was expressed
as the D-value.Di¡erences between groups were deter-
mined by Student’s unpaired t-test or by Mann^Whitney
RENALFUNCTIONINHYPOXAEMICCOPD 311U-test. Di¡erences between subgroups of less than 10
subjects were exclusively determinedbyMann^Whitney
U-test. The importance of di¡erent variables for the
variability of a dependent parameter was determined by
stepwise regression. P-values below 0.05 were consid-
ered signi¢cant.
RESULTS
Before LTOT (n=19)
Lung function and blood gas data are given inTable1. All
but two of the19 patients had severe airway obstruction
with an FEV1 (%P)o40%.Mean PaO2was 7.6371.08kPa.
Fourteen of the19 patients had a PaO2o8.0 kPa. All but
¢ve patients had a PaCO2 o6.5kPa with, mean level
5.9870.85kPa. In 84% of the patients the MnSaO2 was
o90% and about 3/4 of the patients spent more than
50% of the nocturnal recording with an SaO2 below
90%, but only 20% of the patients spent more than 10%
of the night with an SaO2 o85%. Although 74% of the
patients had a restingpulse of at least 80 beats/min, their
mean arterial blood pressurewas slightly and non-signif-
icantly lower (92.0713.0mmHg) compared to that of
the 63-year-old healthy individuals (97.877.4 mmHg). Six
patients were underweight (BMIo20kg/m2) and only
twowere obese (BMI430kg/m2).
Renal function data are given in Table 2. CIn was
35719% and CPAH was 48719% lower than the corre-
sponding clearances in the 63-year-old normal controls.TABLE 2. Renalfunction, salt andwaterexcretionin19COPDp
of LTOTaswell as in healthycontrols
Before LTOT
(n=19)
Befo
(
CIn (ml/min) 64.8717.7*** 65.7
CPAH (ml/min) 243.4769.2*** 242.0
FF (%) 26.574.3*** 26.9
CLi (ml/min) 23.178.5** 22.6
APR (mmol/min) 5.872.7*** 6.0
FPR (%) 61.9717.0** 64.1
ADR (mmol/min) 3.171.2** 3.0
FDR (%) 94.871.9 94.9
S-creatinine (mmol/l) 88.1713.4 91.3
P-sodium (mmol/l) 140.374.9 140.6
U-sodium (mmol/l) 31.6712.0 29.2
U-volume (ml) 10807431.3 1112.6
CNa (ml/min) 1.2370.69* 1.12
Abbreviations: C=clearance; In=inulin; PAH=para-amino-h
F=fractional; PR=proximal sodium reabsorption, DR=distal s
o0.001regarding signi¢cant di¡erences with regard to renal fu
Notethat after the ¢rstthreeparameters, onlycomparisons tot
the di¡erentcontrolgroups, see text.Ref.=upper reference limOn the other hand, FF was 31731% higher than in the
controls (16).
CLi, the absolute proximal (APR) and distal sodium re-
absorptions (ADR), the fractional proximal sodium reab-
sorption (FPR), as well as sodium clearance were
signi¢cantly lower than the mean level of these para-
meters in young healthy individuals (17,18), whereas, the
fractional distal sodiumreabsorption (FDR) didnot di¡er
signi¢cantly from themean level in healthy controls.
The12 patients using diuretics had signi¢cantly higher
theopylline dosage, but lower urinary volume, CNa and
FDR than patients without diuretic treatment (Table 3).
The 11 patients using theofylline did not di¡er from the
seven subjects without this medication with regard to
renal clearancemeasurements.
Correlations
Therewas aweak negative correlationbetweenMnSaO2
and FF (Fig.1) and increasing haemoglobin levels were as-
sociated with increasing FF levels (r=0.52; Po0.05).
FEV1%P correlated negatively with FDR (rs=0.49;
Po0.05). Nocturnal time with SaO2o90% correlated
positively with pulse rate (rs=0.66; Po0.05). CLi, ADR
and total urinary volume increased with increasing MAP
(r-values ranging between 0.54 and 0.58; Po0.05 for all).
CNa was negatively correlated with FDR (rs=0.75,
Po0.01). FPR was positively correlated with CIn, but in-
versely correlated with CLi (rs=0.63 and 0.79; Po0.01
ando0.001resp.). Stepwise regression showed that 67%atientsbefore LTOTandin12 patientsbefore andafter 6months
re LTOT
n=12)
After LTOT
(n=12)
Controls
(n=24)
716.7*** 63.7714.2*** 101.3721.0
764.2*** 249.3754.4*** 491.47108.0
75.1*** 25.873.7** 20.873.5
79.4** 22.378.2*** 29.5
72.5*** 5.871.9*** 12.2
717.0** 63.3716.6** 74.3
71.3** 3.071.1** 3.9
72.0 95.072.5 94.6
714.8 91.1712.5 o120ref.
75.3 139.975.1
710.5 25.1710.2
7497.8 1186.67332.7
70.78* 1.0670.57*** 1.6
ippuric acid; FF=¢ltration fraction; Li=lithium; A=absolute;
odium reabsorption; Na=sodium. *, **, ***=Po0.05, o0.01,
nctional parameters between patients and healthy individuals.
hemeanlevelsinthe controlshavebeenperformed.Regarding
it.
TABLE 3. Signi¢cant di¡erences regarding parameters before treatment (I) between patients treated with diuretics (n=12)
andpatientswithoutthis treatment (n=7) and the percentage of change (D) invariables following LTOT compared to the levels
prior to LTOT, inpatients ontreatmentwith diuretics (n=8) andwithoutdiuretics (n=4)
Diuretics Non-diuretics
CNa (ml/min) (I) 0.9370.46* 1.7470.75
U-volume (ml) (I) 9047394* 13817326
FDR (%) (I) 95.671.6* 93.472.0
Standardbicarb. (mmol/l) (I) 27.771.3* 26.071.5
P-albumin (g/l) (I) 44.674.4* 35.872.9
DFEV1/FVC (%) 12.5712.0* 17.1716.2
DCNa (%) 36.5761.0* 42.5716.7
Abbreviations: seeTables 1 and 2. *Po0.05 regarding di¡erences between the two patient subgroups. A positive D-value
denotes an increased level and a negative D-value denotes a decreased level following LTOT.
FIG. 1. Correlationbetweenpretreatment levels ofmeannoc-
turnal SaO2 (MnSaO2 I) andof ¢ltrationfraction (FFI) (r=0.59;
Po0.05, using simple regression).
312 RESPIRATORYMEDICINEof the variability in FPR before LTOT could be explained
by CLi and a further 27 % could be determined by CIn.
During LTOT (n=12)
MnSaO2 and daytime PaO2 measured during ongoing
oxygen supplement increased signi¢cantly by 7.872.8%
and by 27722% respectively following 6.270.9 months
of LTOT. In allbutonepatientMnSaO2 exceeded 90% and
all but one patient spent less than 25% of the nocturnal
recording with an SaO2o90% and in all12 patients day-
time PaO2 exceeded 8.0 kPa during ongoing oxygen sup-
plement with a mean £ow of 1.570.7 l/min. All but one
patient used the oxygen supplement for at least16h/day.
Neither PaCO2, forced expiratory volumes nor BMI,
pulse rate or blood pressure changed signi¢cantly after
treatment. MAP was now signi¢cantly lower than in
63-year-old controls.Haemoglobin and serum creatinine
levels remained unaltered (Table1).FEV1/FVC declined in patients using diuretics, but in-
creased in patients without this treatment (Table 3).De-
spite this ¢nding, PaCO2 did not change signi¢cantly
(178.5%) in those on diuretics, while it increased by
11.575.4% (Po0.05 (paired t-test)) in four subjects with-
out this treatment.
Renal function as assessed by the clearance measure-
ments and sodium and water excretion (measuredwith-
outoxygen supplement) remainedunchanged following 6
months of LTOT (Table 2). Sodium clearance increased in
patients on diuretics but CNa was reduced in patients
without this therapy (Table 3).
Blood gases taken during ongoing oxygen supplement
showed that in six patients PaCO2 increased by more
than 6% during LTOT and in four this parameter de-
creased or remained unaltered (one patient, in whom
the increase in PaCO2 didnot exceed 6% and another pa-
tient in whom DPaCO2 could not be determined, were
not included in the following subgroup comparison). In
those patients where PaCO2 increased, LTOTwas asso-
ciatedwith a fall inCNa.ConverselyCNa increased follow-
ing LTOT in the other subgroup. Furthermore, the post-
treatment levels of FDR and daytime PaO2 were ele-
vated, whereas the levels of urinary sodium concentra-
tion and nadir nocturnal SaO2 were lower in the
subgroupwith increased PaCO2 compared to other sub-
group (Table 4).
Correlations
Although, LTOT did not bring about any signi¢cant
changes regarding certain parameters for the entire
study group, individual changes (D-values) regarding
theseparameters, couldbehighly and signi¢cantly corre-
lated. Patients with low MnSaO2 before LTOT experi-
enced large post-treatment decrements in FF, while FF
increased in those with relatively high MnSaO2 prior
to LTOT (Fig. 2). The change in FF induced by LTOT
TABLE 4. Signi¢cantdi¡erences regarding variables after4 months of LTOT (II) and the percentage of change inparameters
following LTOT (D-value), between patients with an increase of more than 6% in PaCO2 (n=6) and patients with unaltered or
reduced PaCO2 (n=4) during ongoing oxygen supplementation
DPaCO246% DPaCO2o0%
U-sodium (mmol/l) (II) 18.375.8** 35.078.5
PaO2 (kPa) (II) 9.4970.77** 8.5270.13
Nadir O2 (%) (II) 8074.6* 8772.6
FDR (%) (II) 96.171.6** 92.571.8
DCNa (%) 31739** 55760
DFDR (%) 1.871.8** 22.372.8
Abbreviations: SeeTables1and 2. *, **=P=0.05,o0.05 regardingdi¡erencesbetweenthe twopatient subgroups.
FIG. 2. Spearmanrankcorrelation between pretreatment le-
vels of mean nocturnal SaO2 (MnSaO2 I) and the post-treat-
ment change (increase is denoted by values41.0 and decrease
by valueso1.0) in ¢ltration fraction (DFF II/I) (r=0.73;Po0.05).
FIG. 3. Spearman rank correlation between pretreatment
FEV1/FVC I and the post-treatment change (increase is denoted
by values41.0 and decrease by valueso1.0) in ¢ltration fraction
(DFF II/I) (r=0.71;Po0.05).
RENALFUNCTIONINHYPOXAEMICCOPD 313correlated inversely to pretreatment FEV1/FVC (Fig. 3).
MnSaO2 level duringoxygen supplementcorrelatedposi-
tively with the change in FF following 6 months of LTOT
(rs=0.70;Po0.05).The level of PaO2 during LTOTwas po-
sitivelyrelated to FDR and to S-creatinine, butnegatively
related to CNa during LTOT (r=0.62, 0.56 and 0.65;
Po0.05 for all).The LTOT-induced increments inMnSaO2
correlated with increased FDR (r=0.67; Po0.05). The
post-treatment increase in PaO2 levels was associated
with a reduction in CPAH (rs=0.73;Po0.05).
DPaCO2 levels (measured during ongoing oxygen sup-
plement) following LTOT correlatedpositively with post-
treatment DS-creatinine (rs=0.83, Po0.05). Individual
changes in FEV1/FVC andMAPwere inversely correlated
(r=0.84; Po0.01). Likewise, DFF correlated positively
with DCIn (rs=0.81;Po0.02).
DISCUSSION
The main ¢ndings in the present study are that patients
with hypoxaemic COPD have severe impairments of re-nal function, despite normal serum creatinine levels. Re-
nal function, assessed as ¢ltration fraction is improved
following LTOT, solely in patients with severe nocturnal
hypoxaemia prior to oxygen treatment. This is to our
knowledge the ¢rst study to demonstrate the long-term
e¡ects of oxygen therapy in COPD. Moreover, by mea-
suring CLi (19) the reabsorption of sodium in both the
proximal and indirectly in the distal tubules could for
the ¢rst time be described in hypoxaemic COPD.
The patients in the present study are quite represen-
tative for patients with stable severe chronic airway ob-
struction. The patients had a wide range of PaO2 levels
but only few had substantially increased PaCO2 levels.
No patient had severe oedema of the lower extremities
at the time of the study, but 2/3 of the subjects were
continuously treated with diuretics because of previous
episodes of oedema. In an outlier who also su¡ered from
pulmonary hypertension (see subjects) FF was substan-
tially elevated [to 40.5% (Fig1)].His pulmonary hyperten-
sion may have a¡ected other vascular systems including
the renal microvasculature (20).Our patients continued
their ordinarymedication and diet until the night before
314 RESPIRATORYMEDICINEthe clearance measurements. In other studies, all oral
medication has been discontinued and the patients have
been subjected to a standardised diet for 3 days before
commencement of the renal functional study (1,10,21,22).
However, the e¡ects per se, of such abrupt changes are
unclear. Furthermore, our intention was to clarify the
value of renal clearancemeasurements in normal clinical
practice.
Other researchers have contended that the clearance
methods used in the present study, for example PAH
clearance, are unreliable in diseased states as COPD (6).
However, simultaneousmeasurements inCOPDpatients
regarding the acute e¡ects of oxygen on renal plasma
£ow using Doppler ultrasound and PAH clearance have
shown reasonably good correlation between the two
methods and that both methods seem to accurately re-
£ect changes in renal function (5). Furthermore, the
clearance assessments in the present study were most
probably reliable, given that both water intake and urin-
ary production were closely supervised and that more
than 90% of each of the 45min sampling periods were
properly carried out.
Despite the normal serum creatinine levels, all renal
clearancemeasurements including GFR and renal plasma
£ow were severely diminished in our study. Reduced
muscle mass due to ageing and COPD probably contrib-
uted to the preservation of the normal creatinine levels
(23,24). The expected inverse relationship (11) between
fractional proximal sodium reabsorption (FPR) and CLi
was noted in our patients both before and after treat-
ment. However, FPR was also dependent on GFR, and
GFRwasmore severely impaired compared to CLi (mean
reduction compared to controls: 35% vs. 22%). The re-
duced GFR probably contributed to the reduction in so-
dium load being delivered to the distal part of the
proximal tubules (i.e.CLi), which in turn reduced the ab-
solute reabsorption of sodium from both the proximal
and distal tubules.On the other hand, the reduced abso-
lute sodiumreabsorption couldpartially havebeen coun-
teracted by increased aldosterone levels, which tends to
raise the sodium reabsorption from the distal tubuli (8,1)
and thenetresultmaybe a predominantreduction in the
fractional sodium reabsorption from the proximal tubuli
as found in our study.
There were weak correlations between increased FF
on the one hand and severity of pretreatment nocturnal
hypoxaemia and secondary polycythaemia on the other.
However, there was no correlation between daytime
blood gas aberrations and renal dysfunction, thus sug-
gesting that nocturnal physiological alterations may
sometimes be of greater importance than diurnal ones
for the development of daytime physiological impair-
ments (11,12,25). Like in previous studies (5,10,22) we
found that the elevated FF was due to a more pro-
nounced reduction in renal plasma £ow (i.e.CPAH) than
in glomerular ¢ltration (CIn).The elevated FF is probablyre£ecting increased renal vascular resistance, possibly in
turn due to e¡erent renal arteriolar vasoconstriction
(5,9,22). However, this vasoconstriction was alleviated
solely in subjectswith severepretreatmentnocturnal hy-
poxaemia (including the above-mentioned outliner) (Fig.
2).This ¢ndingmay imply that factors other than hypox-
aemia are of importance for the renal e¡erent arteriolar
vasoconstriction. First of all, studies in healthy subjects
imply that increased breathing e¡ort in itself may alter
renalblood £ow (26). Severe chronic air£ow obstruction
and hyperin£ation is accompanied by increased basal in-
spiratory pressure and thus, probably elevated work of
breathing (27).
Second, severe airway obstruction is associated with
elevated end-expiratory alveolar pressure, in turn asso-
ciatedwith decreased venous return and oedema forma-
tion of the lower extremities (28). In several studies of
COPD patients, it has been found that degree of im-
paired renal function is related not only to blood gas dis-
turbances, but also to the severity of air£owobstruction
(1,8,22). The patients in our study with the most severe
air £ow obstruction had the most elevated post-treat-
ment FF.
Third, the reduced venous return may be counter-
acted by altered baro-receptor re£exes, which possibly
in conjunction with increased catecholamine secretion
will lead to increased pulse ratewhich in turnwill prohi-
bit a severe decrease in systemic vascular pressures.
Thus, a further fall in salt delivery to the renal tubules
and urinary output will be prevented (8,12). In our study
increasing MAP was associated with increases in CLi and
in urinary volume and neither MAP nor pulse rate was
altered by LTOT.
Fourth, already mild to moderate hypercapnia may
contribute to renal vasoconstriction, as has been noted
in the present and in previous studies of COPD patients
(8,22).
Fifth, chronic air £ow obstruction as well as impaired
gas exchange may give rise to numerous hormonal ab-
normalities. These may consist of increases in sympa-
thetic nervous norepinephrine (NE) secretion (11),
endothelin production (9), plasma renin activity, aldos-
terone and antidiuretic hormone secretion (1,8) as well
as reduced production of atrial natriuretic peptide
(ANP) (21) and possibly of diminished renal NO produc-
tion (29). The importance of all of these factors for the
long-term evolution of renal function in severe hypoxae-
mic COPD is largely unknown. Long-term treatment
withACE inhibitors in order to decrease therenal vascu-
lar pressures seems not to be bene¢cial for the renal
function in severe COPD (30). Nevertheless, LTOT for
at least 4 months reduces NE excretion but only if the
nocturnal oxygenation is substantially improved (11).
Whether there exists an association in COPD between
NE excretion and renal vasoconstriction, assessed by in-
creased ¢ltration fraction, remains to be elucidated.
RENALFUNCTIONINHYPOXAEMICCOPD 315Finally, in hypoxaemic COPD, the balance between re-
nal oxygen delivery and renal oxygen consumption may
be severely disturbed and, thus, aggravatedkidney tissue
hypoxia may ensue (31).
Intravenous infusions of theofyllinemight increase na-
triuresis (32) but, long-term oral theophylline treatment
seems to be of little consequence for sodium excretion
(33). In the present study, the sodium clearance and the
other clearancemeasurements didnotdi¡er signi¢cantly
between those treated with slow-release theophylline
and thosewithout theophylline.
Treatmentwith diuretics seems toberather related to
the severity of airwaydisease (21) as judgedby the higher
use of theofylline and the continuous deterioration in
airway obstruction in our subgroup on diuretic treat-
ment compared to the patients without diuretics. De-
spite continuous treatment with diuretics, these
patients, prior to LTOT, exhibited reduced ability to
excrete a water load and their sodium clearance was
probably antagonisedby anelevated fractional distal tub-
ular sodium reabsorption (FDR) rate. These ¢ndings
should not be considered as indicating that treatment
with diuretics in COPD patients with oedema is of no
avail (22), since clinical experience, as well as several
studies, has shown bene¢cial e¡ects of diuretics on kid-
ney function particularly in exacerbations of COPD (2).
Continuous treatment with diuretics in our stable
COPD patients was associated with unchanged PaCO2
levels after 6 months of LTOT, whereas patients without
diuretics exhibited raised PaCO2 levels after LTOT.The in-
crease in CNa following LTOT in the subgroup treatedwith
diuretics may suggest that normalisation of the arterial
oxygenation is a prerequisite for achieving e¡ective renal
tubular salt andwater excretion using loop diuretics (2).
Higher levels of diurnal and nocturnal oxygenation
during LTOTwere surprisingly enough associated with
deterioration in renal function as manifested by raised
post-treatment FF and FDR and diminished CNa. Our
¢ndings are probably not due to a detrimental e¡ect of
the improved oxygenation in itself, but rather due to
the harmful e¡ect of a mean post-treatment increase in
daytime PaCO2 of14% in half of our patients. In this sub-
group of our patients a reduced CNa and high post-treat-
ment FDR were noted, whereas sodium clearance
increased and FDR decreased in patientswith decreased
PaCO2 during LTOT.Thus, even ratherminor increments
in PaCO2may impair the renalmicrocirculation (22).The
choice of a cut-o¡ point of 46% for the increase in
PaCO2 following LTOTwas based on a previous study
(34) showing that 6^8% is a common level for the in-
crease in PaCO2 in COPD patients given LTOT.
The elevated FDR in our hypercapnic patients sug-
gests that such patients have smaller reserve capacity
for excreting additional water and salt loads (6,8,22). In
individuals with increased GFR following LTOTand thus
increased in£uxof £uid and electrolytes, FF tended to in-crease, probablybecause the renal vasculature to a great
extent remained in a constricted and rigid state.
The lower nadir nocturnal SaO2 in the subgroup with
post-treatment increments in daytime PaCO2 may imply
that this subgroup su¡ered from substantial alveolar hy-
poventilation (34), leading to substantial nocturnal hy-
percapnia (35).
In conclusion, hypoxaemic COPD patients have im-
paired renal function, demonstrated by reduced glomer-
ular ¢ltration rate, renal plasma £ow and sodium
clearance. The FF is elevated, probably due to vasocon-
striction of e¡erent renal arterioles. Six months of LTOT
is accompanied by a reduction in FF solely in patients
with severe pretreatment nocturnal hypoxaemia. Post-
treatment sodium clearance seems to be increased, gi-
ven that the improved oxygenation is not accompanied
by raised PaCO2-levels.
Acknowledgements
We extend our gratitude to the nurses of the depart-
ment of Renal Medicine for excellent assistancewith the
renal clearancemeasurements.
REFERENCES
1. Farber MO, Roberts LR, Weinberger MH, Robertson GL, Fineberg
NS, Manfredi F. Abnormalities of sodium and H2O handling in
chronic obstructive lung disease. Arch InternMed 1982; 142: 1326–
1330.
2. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of
congestive state in chronic obstructive pulmonary disease. Circu-
lation 1996; 86: 12–21.
3. Weitzenblum E, Aprill M, Oswald M, Chaouat A, Imbs J-L.
Pulmonary hemodynamics in patients with chronic obstructive
pulmonary disease before and during an episode of peripheral
edema. Chest 1994; 105: 1337–1382.
4. Baudouin SV, Bott J, Ward A, Deane C, Moxham J. Short term
effect of oxygen on renal haemodynamics in patients with
hypoxaemic chronic obstructive arways disease. Thorax 1992; 47:
550–554.
5. Howes TQ, Deane CR, Lein GE, Baudouin SV, Moxham J. The
effects of oxygen and dopamine on renal and aortic blood flow in
chronic obstructive pulmonary disease with hypoxemia and
hypercapnia. Am J Respir Crit Care Med 1995; 151: 378–383.
6. Sharkey RA, Mulloy EMT, Kilgallen IA, O’Neill SJ. Renal functional
reserve in patients with severe chronic obstructive pulmonary
disease. Thorax 1997; 52: 411–415.
7. Farber MO, Weinberger MH, Robertson GL, Fineberg N. The
effects of angiotensin-converting enzyme inhibition on sodium
handling in patients with advanced chronic obstructive pulmonary
disease. Am Rev Respir Dis 1987; 136: 862–866.
8. Stewart AG, Waterhouse JC, Billings CG, Baylis PH, Howard P.
Hormonal, renal and autonomic nerve factors involved in the
excretion of sodium and water during dynamic salt and water
loading in hypoxaemic chronic obstructive pulmonary disease.
Thorax 1995; 50: 838–845.
9. Cargill RI, Kiely DG, Clark RA, Lipworth BJ. Hypoxaemia and
release of endothelin-1. Thorax 1995; 50: 1308–1310.
10. Mannix ET, Dowdeswell I, Carlone S, Palange P, Aronoff GR,
Farber MO. The effect of oxygen on sodium excretion in
316 RESPIRATORYMEDICINEhypoxemic patients with chronic obstructive lung disease. Chest
1990; 97: 840–844.
11. Bratel, T, Carlstro¨m K, Wennlund A. Impact of hypoxaemia on
neuroendocrine function and catecholamines in chronic obtsruc-
tive pulmonary disease (COPD). Effects of long-term oxygen
treatment. Respir Med 2000; 94: 1221–1228
12. Fletcher EC, Luckett RA, Miller T, Costarangos C, Kutka N,
Fletcher N. Pulmonary vascular hemodynamics in chronic lung
disease with and without oxhemoglobin desaturation during sleep.
Chest 1989; 95: 757–764.
13. Follenius M, Krieger J, Krauth MO, Sforza F, Brandenberger G.
Obstructive sleep apnea treatment: peripheral and central
effects on plasma renin activity and aldosterone. Sleep 1991; 14:
211–217.
14. Grunstein RR, handelsman DJ, Lawrence SJ, Blackwell C, Caterson
ID, Sullivan CE. Neuroendocrine dysfunction in sleep apnea:
reversal by continuous positive airway pressure therapy. J Clin
Endocrinol Metabol 1989; 68: 352–358.
15. Timms RM, Khaja FU, Williams GW, the Nocturnal Oxygen
Therapy Trial Group. Hemodynamic response to oxygen therapy
in chronic obstructive pulmonary disease. Ann Intern Med 1985;
102: 29–36.
16. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effects of
intensified blood-pressure reduction on renal function and albumin
excretion in primary hypertension. Addition of felodipine
or ramipril to long-term b-blockade. Am J Hypertens 1995; 8:
113–123.
17. Stenvinkel P, Saggar-Malik AK, Alvestrand A. Renal haemody-
namics and tubular sodium handling following expansion with
sodium chloride (NaCl) and glucose in healthy humans. Scand JClin
Lab Invest 1992; 52: 837–846.
18. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A. Renal hemo-
dynamics and sodium handling in moderate renal insufficiency. The
role of insulin resistance and dyslipidemia. J Am Soc Nephrol 1995;
5: 1–10.
19. Thomsen K. Lithium clearance: a new method for determining
proximal and distal tubular reabsorption of sodium and water.
Nephron 1984; 37: 217–223.
20. Sakamoto K, Houya I, Inoue K, Tanaka M, Susuki T, Sakamoto Y,
Matsuo H. An imbalance in plasma prostanoids in patients with
Raynaud’s phenomenon and pulmonary vasospasm. Eur Resp J
1999; 13: 137–144.
21. Stewart AG, Bardsley PA, Baudouin SV, Waterhouse JC,
Thompson JS, Morice AH, Howard P. Changes in atrial natriuretic
peptide concentrations during intravenous saline infusion in
hypoxic cor pulmonale. Thorax 1991; 46: 829–834.
22. Adnot S, Sediame S, Defouilloy C, et al. Role of atrial natriuretic
factor in impaired sodium excretion in normocapnic and
hypercapnic patients with chronic obstructive lung disease. Am
Rev Respir Dis 1993; 148: 1049–1055.23. Lindeman RD. Assessment of renal function in the old. Special
considerations. Clin Lab Med 1993; 13: 269–277.
24. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is
a reversible factor in the prognosis of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1791–
1797.
25. Fitzpatrick MF, Mackay T, Whyte KF, etal. Nocturnal desaturation
and erythropoietin: a study in patients with chronic obstructive
pulmonary disease and in normal subjects. Clin Sci 1993; 84: 319–
324.
26. Vidiendal Olsen N, Christensen H, Klausen T, Fogh-Andersen N,
Plum I, Kanstrup IL, Melchior Hansen J. Effects of hyperventilation
and hypocapnic/normocapnic hypoxemia on renal function and
lithium clearance in humans. Anesthesiology 1989; 89: 1389–1400.
27. Sandek K, Andersson T, Bratel T, Hellstro¨m G, Lagerstrand L.
Sleep quality, carbon dioxide responsiveness and hypoxaemic
patterns in nocturnal hypoxaemia due to chronic obstructive
pulmonary disease (COPD) without daytime hypoxaemia. Respir
Med 1999; 93: 79–87.
28. Ranieri VM, Dambrosio M, Brienza N. Intrinsic PEEP and
cardiopulmonary interaction in patients with COPD and acute
ventilatory failure. Eur Respir J 1996; 9: 1283–1292.
29. Howes TQ, Keilty SEJ, Maskrey VL, Deane CR, Baudouin SV,
Moxham J. Effect of L-arginine on renal blood flow in normal
subjects and patients with hypoxic chronic obstructive pulmonary
disease. Thorax 1996; 51: 516–519.
30. Stewart AG, Waterhouse JC, Billings CG, et al. Effects of
angiotensin converting enzyme inhibition on sodium excretion in
patients with chronic obstructive pulmonary disease. Thorax 1994;
49: 995–998.
31. Pham I, Andrivet P, Sediame S, et al. Increased erythropoietin
synthesis in patients with COLD or left heart failure is related to
alterations in renal haemodynamics. Eur JClin Invest 2001; 31: 103–
109.
32. Beutler JJ, Koomans HA, Bijlsma JA, Dorhout Mees EJ. Renal
actions of theophylline and atrial natriuretic peptide in humans: a
comparison by means of clearance studies. J Pharmacol ExpTher
1990; 255: 1314–1319.
33. Stanley AJ, Forrest EH, Dabos KJ, MacGilchrist AJ, Hayes PC.
Comparison between theophylline and spironolactone in the
management of cirrhotic ascites: a randomized controlled study.
Aliment Pharmacol Ther 1998; 12: 389–393.
34. Sandek K, Bratel T, Hellstro¨m G, Lagerstrand L. Ventilation–
perfusion inequality and carbon dioxide sensitivity in hypoxaemic
chronic obstructive pulmonary disease (COPD) and effects of
long-term oxygen treatment (LTOT) for six months. Clin Physiol
2001; 5: 584–593.
35. Mulloy E, McNicholas WT. Theophylline improves gas exchange
during rest, exercise and sleep in severe chronic obstructive
pulmonary disease. Am Rev Resp Dis 1993; 148: 1030–1036.
